Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Perspective Therapeutics, Inc.AMEX: CATX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns positive

Q1 FY2026 net change in cash was $23.34M, compared with -$17.17M a year earlier. Trailing-twelve-month net change in cash was $9.57M.

Context

  • Net change in cash amounted to 3501.2% of revenue in FY2025, down 86.1 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near $23.34M or moves back toward the trailing-twelve-month quarterly average of $2.39M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.34M+503.6% QoQ
Last fiscal yearDec 2025
-$30.95M-159.3% YoY
LTMMar 2026
$9.57M+109.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+235.9%——
1 year-159.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(30.95M) USD
Year-over-year change
-159.3%

Net Change in Cash vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 net change in cash of $9.57M is the 4th largest of the 5 companies compared; the peer median is $13.9M.
  • Its year-over-year change of +109.8% is the 3rd highest of 5, against a peer median of +146.1%.
  • Net change in cash amounts to 1547.9% of revenue for CATX, versus a peer median of 18.2%.
CATX Competitors Peer median
Net Change in Cash for CATX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$43.55M +382.3%—97.0%
NVCRNovoCure LimitedLTM Mar 2026$32.11M -90.2%-12.6%4.8%
DCTHDelcath Systems, Inc.LTM Mar 2026$28.54M +2854.1%—31.6%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.57M +109.8%—1547.9%
SRTSSensus Healthcare, Inc.LTM Mar 2026$745K -117.2%-86.5%3.3%
Peer median (excluding CATX) $13.9M+146.1%-49.5%18.2%

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.27M)(14.67M)(46.51M)(79.28M)(103.12M)
Depreciation & Amortization248K344K946K2.31M3.25M
Deferred Income Tax0(1.68M)(2.65M)(2.1M)(793K)
Stock-Based Compensation1.09M1.34M3.74M5.39M8.97M
Change in Working Capital(1.85M)338K2.3M31.81M1.68M
Accounts Receivables405K490K(426K)1.05M(32K)
Inventory(2.67M)(152K)359K11K0
Accounts Payables236K01.58M1.89M147K
Other Working Capital182K(28K)779K29.74M1.57M
Other Non-Cash Items77K472K5.27M55.39M7.53M
Operating Cash Flow(7.71M)(12.17M)(36.91M)(18.29M)(82.48M)
Capital Expenditures(266K)(302K)(1.07M)(54.41M)(12.75M)
Acquisitions (Net)002.7M00
Purchases of Investments000(243.51M)(119.84M)
Sales of Investments0022.76M0173.95M
Other Investing Activities(18K)(57.38M)(18K)78.99M(135K)
Investing Cash Flow(284K)(57.68M)24.37M(218.93M)41.23M
Debt Repayment——(68K)(48K)(52K)
Common Stock Issued56K0364K275.81M10.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities056K489K289.39M0
Financing Cash Flow56K56K785K289.39M10.31M
Effect of Forex Changes061.86M000
Net Change in Cash(7.94M)182K(46.65M)52.16M(30.95M)
Free Cash Flow(7.98M)(12.47M)(37.99M)(72.71M)(95.23M)

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.